Eli Lilly and Company
LLY
$1148.84
-0.53%
Eli Lilly & Co. is a global pharmaceutical leader focused on neuroscience, cardiometabolic, cancer, and immunology, with key products including Mounjaro, Zepbound, Verzenio, and Taltz. As a top-tier drug manufacturer, Lilly distinguishes itself through a dominant position in the GLP-1 weight-loss and diabetes market, driving explosive revenue growth and market-cap expansion. The current investor narrative centers on the accelerating adoption of its obesity and diabetes franchise, which now accounts for nearly two-thirds of revenue, alongside strategic acquisitions and pipeline advancements that fuel debates about growth sustainability and competitive threats from oral alternatives.…
LLY
Eli Lilly and Company
$1148.84
Related headlines
LLY 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Eli Lilly and Company's 12-month outlook, with a consensus price target around $1276.96 and implied upside of +11.2% versus the current price.
Average Target
$1276.96
0 analysts
Implied Upside
+11.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$850 - $1600
Analyst target range
The stock is covered by 27 analysts, with a consensus recommendation of 'Buy' (mean rating 1.76 on a 1-5 scale). The average target price is $1,270.37, implying +6.2% upside from the current price of $1,196.03. The distribution leans heavily bullish, with recent ratings from Citigroup, UBS, and Morgan Stanley all reiterating Buy/Overweight. The target range spans from a low of $850.00 to a high of $1,600.00. The high target of $1,600 assumes continued GLP-1 dominance, pipeline success, and multiple expansion, while the low target of $850 reflects risks from competition (e.g., oral Wegovy), pricing pressure, or pipeline setbacks. The wide spread ($750) indicates high uncertainty about the pace of growth and competitive dynamics. Recent institutional ratings show no downgrades; all 10 listed firms maintain positive stances, with actions like 'Buy' and 'Overweight' reaffirmed in July 2026, signaling strong near-term conviction.
Drowning in data?
Find the real signal!
Bulls vs Bears: LLY Investment Factors
Eli Lilly presents a compelling growth story anchored by its dominant GLP-1 franchise, with revenue accelerating to 55.5% YoY growth and margins expanding rapidly. The bull case is supported by strong analyst consensus, a low beta providing defensive characteristics, and a PEG ratio below 1.0 suggesting undervaluation relative to growth. However, the bear case highlights extreme concentration risk in GLP-1 drugs, a premium valuation versus peers, and emerging competitive threats from oral alternatives and pipeline candidates. The single most important tension is whether Lilly can sustain its GLP-1 leadership through innovation (oral formulations, next-gen molecules) and pipeline diversification, or if competition and pricing pressure will erode its growth trajectory. Currently, the bull case has stronger evidence given the accelerating revenue and margin expansion, but the wide analyst target range reflects high uncertainty.
Bullish
- Explosive Revenue Growth: Q1 2026 revenue surged 55.5% YoY to $19.80B, accelerating from 22.2% in Q4 2025 and 13.1% in Q3 2025, driven by the GLP-1 franchise (Mounjaro/Zepbound) which now accounts for 79.6% of total revenue.
- Expanding Profit Margins: Net margin improved to 37.4% in Q1 2026 from 21.7% a year ago, while operating margin expanded to 44.7% from 42.5%, demonstrating strong operating leverage as revenue scales.
- Strong Analyst Conviction: 27 analysts rate the stock a consensus Buy (mean 1.76 on 1-5 scale) with an average target of $1,270.37, implying 6.2% upside. No recent downgrades; all major firms maintain Overweight/Buy.
- Low Beta Defensive Growth: With a beta of 0.51, the stock offers growth with significantly lower market correlation than typical high-growth names, providing downside protection during market selloffs.
Bearish
- Extreme Revenue Concentration: GLP-1 drugs (Mounjaro/Zepbound) represent 79.6% of Q1 2026 revenue, creating significant single-product-line risk if competition intensifies or pricing pressure emerges.
- Premium Valuation vs Peers: Trailing P/E of 46.7x is a 112% premium to the drug industry median of ~22x, leaving little room for error. Any growth deceleration could trigger multiple compression.
- Competitive Threat from Oral GLP-1s: Oral Wegovy's strong launch challenges Lilly's injectable dominance, and Viking Therapeutics' VK2735 shows superior efficacy with dual-formulation potential, threatening market share.
- High Debt-to-Equity Ratio: Debt-to-equity of 1.60x is elevated for a pharma company, and interest expense of $332M in Q1 2026 could pressure earnings if rates remain high or debt is refinanced at higher costs.
LLY Technical Analysis
The stock is in a strong uptrend, with a 1-year price change of +48.5%, significantly outperforming the S&P 500's +16.5%. Currently trading at $1,196.03, it sits at 95.7% of its 52-week range ($623.78–$1,249.45), indicating the stock is near its highs and reflecting robust momentum. This positioning near the top of the range suggests bullish sentiment but also potential overextension, warranting caution for new entries. Short-term momentum is accelerating: the 1-month change is +7.1% and the 3-month change is +35.3%, both well above the S&P 500's +0.8% and +3.5% respectively. The 1-month relative strength of +6.3% confirms near-term outperformance, while the 3-month trend aligns with the longer-term uptrend, showing no divergence. The stock's beta of 0.51 indicates it is significantly less volatile than the market, which is unusual for a high-growth stock but may reflect its defensive healthcare nature. Key support is at the 52-week low of $623.78, while resistance is at the 52-week high of $1,249.45. A breakout above $1,249.45 would signal a continuation of the uptrend, while a breakdown below recent support near $1,100 could indicate a pullback. The low beta suggests that even in market downturns, Lilly may hold up relatively well.
Beta
0.51
0.51x market volatility
Max Drawdown
-23.3%
Largest decline past year
52-Week Range
$624-$1249
Price range past year
Annual Return
+55.2%
Cumulative gain past year
| Period | LLY Return | S&P 500 |
|---|---|---|
| 1m | -3.6% | +0.2% |
| 3m | +19.3% | +3.7% |
| 6m | +10.8% | +8.0% |
| 1y | +55.2% | +18.2% |
| ytd | +6.3% | +9.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
LLY Fundamental Analysis
Revenue growth is accelerating sharply: Q1 2026 revenue was $19.80 billion, up 55.5% year-over-year, compared to Q1 2025 revenue of $12.73 billion. This marks a significant acceleration from the 22.2% YoY growth in Q4 2025 and 13.1% in Q3 2025. The cardiometabolic segment, driven by Mounjaro and Zepbound, generated $15.76 billion in the latest quarter, representing 79.6% of total revenue, while oncology contributed $2.27 billion and immunology $1.20 billion. The growth trajectory is robust, but concentration risk in GLP-1 drugs is a key debate. Profitability is strong and improving: net income in Q1 2026 was $7.40 billion, with a net margin of 37.4%, up from 21.7% in Q1 2025. Gross margin remains high at 81.9%, slightly below the 82.5% in Q1 2025 but still excellent. Operating margin expanded to 44.7% from 42.5% a year ago, reflecting operating leverage. The company is solidly profitable with expanding margins, typical for a successful pharma company. The balance sheet is healthy but leveraged: debt-to-equity is 1.60, and the current ratio is 1.58, indicating adequate liquidity. Free cash flow (TTM) is $13.58 billion, with a free cash flow yield of 1.4% based on current market cap. ROE is an exceptional 77.8%, driven by high profitability and leverage. The company generates substantial cash to fund growth and acquisitions, as seen in the recent AtaiBeckley deal, but the debt load requires monitoring.
Quarterly Revenue
$19.8B
2026-03
Revenue YoY Growth
+55.5%
YoY Comparison
Gross Margin
81.9%
Latest Quarter
Free Cash Flow
$13.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is LLY Overvalued?
Since net income is positive ($7.40 billion), the primary valuation metric is the P/E ratio. The trailing P/E is 46.7x, while the forward P/E is 26.7x, implying the market expects significant earnings growth. The gap between trailing and forward P/E suggests that the market is pricing in a sharp earnings increase, which aligns with the 55.5% revenue growth. Compared to the industry average (Drug Manufacturers - General), Lilly's trailing P/E of 46.7x is a premium to the sector median of roughly 22x, representing a 112% premium. This premium is justified by superior growth (55.5% YoY revenue growth vs. industry average of ~10%) and exceptional profitability (net margin 37.4% vs. industry average ~15%). Historically, Lilly's trailing P/E has ranged from 28x to 205x over the past three years. The current 46.7x is near the lower end of its historical range, suggesting that despite the high absolute multiple, it is not stretched relative to its own history. This implies the market has already priced in some growth deceleration, but the forward P/E of 26.7x indicates further earnings expansion is expected.
PE
46.7x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 28x~76x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
35.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Lilly's financial profile shows strong profitability but elevated leverage. Debt-to-equity of 1.60x is high relative to pharma peers, and interest expense of $332M in Q1 2026 consumes a meaningful portion of operating income ($8.85B). While free cash flow of $13.58B TTM provides ample coverage, any sustained rise in interest rates or debt refinancing at higher costs could pressure net income. The 79.6% revenue concentration in GLP-1 drugs (Mounjaro/Zepbound) is a critical operational risk; a setback in this franchise—whether from competition, pricing pressure, or manufacturing issues—would disproportionately impact total revenue and earnings. Gross margin of 81.9% is strong but slightly down from 82.5% a year ago, suggesting potential mix shift or pricing dynamics that warrant monitoring.
Market & Competitive Risks: The stock's trailing P/E of 46.7x represents a 112% premium to the drug industry median of ~22x, making it vulnerable to valuation compression if growth decelerates. The low beta of 0.51 provides some insulation from broad market selloffs, but the stock is highly sensitive to GLP-1-specific news. Competitive threats are intensifying: oral Wegovy's strong launch directly challenges Lilly's injectable dominance, and Viking Therapeutics' VK2735 has shown superior efficacy with both injectable and oral formulations in development. Regulatory risks include potential pricing reforms for obesity drugs and Medicare expansion details, though recent Medicare coverage expansion for obesity medications is a positive catalyst. The wide analyst target range ($850-$1,600) underscores the high uncertainty around competitive dynamics and growth sustainability.
Worst-Case Scenario: In a severe adverse scenario, oral GLP-1 competitors capture significant market share, pricing pressure erodes margins, and pipeline candidates fail to deliver. Revenue growth could decelerate sharply, leading to multiple compression. The realistic downside is to the 52-week low of $623.78, representing a -47.8% decline from the current price of $1,196.03. This aligns with the analyst low target of $850, implying a -28.9% downside. Historical max drawdown of -23.31% provides a less severe but still significant reference. An investor could lose up to 48% of their investment in a worst-case scenario, though the low beta and strong fundamentals suggest this is a low-probability event.
